According to a recent market analysis, the global oral controlled release drug delivery technology market is on track to experience substantial growth, projected to reach USD 68.4 billion by 2032 from USD 34.1 billion in 2022. This surge represents a robust 7.2% compound annual growth rate (CAGR) over the forecast period.
The anticipated expansion is primarily driven by the escalating prevalence of chronic diseases worldwide, alongside a growing preference for oral drug delivery. Compared to alternative administration methods, oral delivery offers unmatched convenience, cost-effectiveness, and enhanced patient compliance, thereby fueling its adoption across diverse healthcare settings.
Request A Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4400
As the global healthcare landscape continues to evolve, the demand for innovative drug delivery solutions is at an all-time high. Oral controlled release drug delivery technology stands out as a frontrunner, offering a promising avenue for pharmaceutical companies and healthcare providers to meet the evolving needs of patients efficiently.
“The projected growth of the global oral controlled release drug delivery technology market underscores the increasing importance of patient-centric solutions in healthcare,” said FMI. “This market expansion presents significant opportunities for stakeholders to innovate and collaborate in developing advanced drug delivery technologies that enhance patient outcomes and drive positive healthcare outcomes globally.”
With its potential to revolutionize drug delivery and improve patient care, the global oral controlled release drug delivery technology market is primed for substantial growth and innovation in the years ahead.
Market Outlook: Potential and Opportunities
The burgeoning oral controlled release drug delivery technology market presents exciting opportunities for pharmaceutical companies, research institutions, and investors. Continuous advancements in technology and the development of novel drug delivery systems are expected to further fuel market growth. Additionally, the increasing focus on personalized medicine and targeted therapies is likely to create further demand for specialized controlled release solutions.
In conclusion, the oral controlled release drug delivery technology market is poised for remarkable growth, driven by the rising burden of chronic diseases and the inherent benefits of oral drug delivery. With solid dosage forms leading the charge and advancements in technology paving the way, this market holds immense potential for stakeholders across the healthcare spectrum.
Get Customization on This Report: https://www.futuremarketinsights.com/customization-available/rep-gb-4400
Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market:
By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system. Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass USD 10,000 Million in 2017. Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.
Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027. Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.
Key Market Players Identified in FMI’s Report Include:
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Sun Pharmaceuticals Industries Ltd
- Abbott Laboratories
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Mylan N.V.
- Sanofi
- F. Hoffman-La-Roche Ltd.
- Johnson & Johnson Services, Inc.
- Vectura Group plc.
- GlaxoSmithKline plc.
Market Taxonomy:
By Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- MEA
By Drug Release System
- Diffusion Controlled Release System
- Dissolution Controlled Release System
- Osmotically Controlled Release System
- Dissolution & Diffusion Controlled Release System
- Ion Exchange Resins Controlled Release
- Hydro-dynamically Balanced Drug Delivery System
- Others
A Full Report Overview: https://www.futuremarketinsights.com/checkout/4400
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
